PioneeringAdvanced TherapyMedicinalProducts (ATMPs)
TheAEScleanroomhasservedasthecriticalenvironmentto protecteachofthesefirst-of-its-kindimmunotherapiesthat theUnitedStatesFDAhasapprovedtotreatpatientswith debilitatingdiseases.
2010
DendreonCorporation
ThefirstFDA-approvedautologous celltherapywasapprovedin2010 forthetreatmentofmetastatic prostatecancers.
2017
SparkTherapeutics
ThefirstFDA-approvedgene therapyapprovedin2017for thetreatmentofinherited retinaldisease.
2018
Novartis/PENNMedicine
ThefirstFDA-approvedCAR-Tcell therapyapprovedin2018forthe treatmentofacutelymphoblastic leukemia,largeB-celllymphoma, andfollicularlymphoma.
2024
ThefirstFDA-approvedtumorinfiltratinglymphocyte(TIL)therapy approvedin2024forthetreatment ofadvancedmetastaticmelanoma.
Eachofthesedrugsleveragedanewmodalitythatishelping tocreateanddelivernewtreatments,includingultimate cures.AEShasbeenattheforefrontinthegenesisofthese technologiesthathavetransformedmedicine,andweare proudofourroleinenablingthislife-changingsciencetobe pioneeredinsideofourfacilities.
TolearnmoreaboutAESCleanTechnologyandhowit
